Chemotherapy-associated nausea and vomiting, prevention

Antiemetic; Selective 5-HT3 Receptor Antagonist
Selective 5-HT3-receptor antagonist, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone.

1.Onset of action: IV: 1 to 3 minutes.
2.Duration: Oral, IV: Generally up to 24 hours.
3.Distribution: Vd: 2 to 4 L/kg; widely throughout body.
4.Protein binding: ~65%.
5.Metabolism: Hepatic via CYP1A1 and CYP3A4 N-demethylation, oxidation, and conjugation; some metabolites may have 5-HT3 antagonist activity.
6.Half-life elimination: Oral: 6 hours; IV: Mean range: 5 to 9 hours; SUBQ (extended release): ~24 hours.
7.Excretion: Urine (11% to 12% as unchanged drug, 48% to 49% as metabolites); feces (34% to 38% as metabolites)

Hypersensitivity to granisetron or any component of the formulation or to other 5-HT3 receptor antagonists.

Available evidence is inconclusive or inadequate for determining fetal risk when used in pregnant women.

Infant risk cannot be ruled out.

Asthenia, Headache, Somnolence, Fever

Chemotherapy-associated nausea and vomiting, prevention
IV: 10 mcg/kg within 30 minutes prior to chemotherapy; only on the day(s) chemotherapy is administered.

No dosage adjustment necessary.

No dosage adjustment necessary.